SCHEMBL1386922

SCHEMBL1386922

Fc1ccc(-c2nc3[nH]ncc3c(-c3ccco3)c2-c2ccncc2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA1 P30542 7/20 0.46
ADORA2A P29274 6/20 0.46
ADORA2B P29275 6/20 0.45
MAPK14 Q16539 10/20 0.42
KDM4E B2RXH2 1/20 0.39
ALDH1A1 P00352 1/20 0.39
MAPT P10636 1/20 0.39
HSD17B10 Q99714 1/20 0.39
MAPK11 Q15759 3/20 0.39
MAPK13 O15264 2/20 0.39
MAPK12 P53778 2/20 0.39
ADORA3 P0DMS8 3/20 0.39
MAPK10 P53779 1/20 0.39
NPC1 O15118 1/20 0.38
TSHR P16473 1/20 0.38
RAB9A P51151 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
CSNK1D P48730 1/20 0.38
EGFR P00533 1/20 0.37
RAF1 P04049 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29652689 0.86 MAPK14 (0.48) ADORA1ADORA2AADORA2BMAPK14MAPK11
SCHEMBL2931861 0.86 MAPK14 (0.48) ADORA1ADORA2AADORA2BMAPK14MAPK11
SCHEMBL1384940 0.82 KDM4E (0.41) ADORA1ADORA2AADORA2BMAPK14KDM4E
SCHEMBL1386461 0.82 MAPK14 (0.53) ADORA1ADORA2AADORA2BMAPK14MAPK11
SCHEMBL1386446 0.81 MAPK14 (0.49) ADORA1ADORA2AADORA2BMAPK14KDM4E
SCHEMBL2930581 0.80 POLB (0.46) ADORA1ADORA2AADORA2BMAPK14MAPK11
SCHEMBL1386787 0.77 HSD17B1 (0.44) ADORA1ADORA2AADORA2BMAPK14KDM4E
SCHEMBL1384646 0.77 MAPK14 (0.40) MAPK14MAPK11MAPK13MAPK12MAPK10
SCHEMBL2929925 0.77 MAPK14 (0.40) ADORA1ADORA2AADORA2BMAPK14MAPK11
SCHEMBL1386702 0.77 MAPK14 (0.46) ADORA1ADORA2AADORA2BMAPK14KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8536194-B2 Pyrazolopyridine derivates PALAU PHARMA, S.A. (ES) 2013-09-17 US claimed
JP-4814783-B2 2011-11-16 JP claimed
EP-1611131-B1 PYRAZOLOPYRIDINE DERIVATES PALAU PHARMA SA (ES) 2010-09-15 EP claimed
US-20090005377-A1 Pyrazolopyridine Derivates PALAU PHARMA, S.A. (ES) 2009-01-01 US claimed
US-7468376-B2 Pyrazolopyridine derivates PALAU PHARMA, S.A. (ES) 2008-12-23 US claimed
US-20060167040-A1 Pyrazolopyridine derivates J. URIACH Y COMPANIA S.A. (ES) 2006-07-27 US claimed
EP-1611131-A1 PYRAZOLOPYRIDINE DERIVATES J. Uriach y Compagnia S.A. (ES) 2006-01-04 EP claimed
WO-2004076450-A1 PYRAZOLOPYRIDINE DERIVATES J. Uriach Y Compañia S.A. (ES) 2004-09-10 WO claimed
US-8536194-B2 Pyrazolopyridine derivates PALAU PHARMA, S.A. (ES) 2013-09-17 US disclosed
EP-1611131-B1 PYRAZOLOPYRIDINE DERIVATES PALAU PHARMA SA (ES) 2010-09-15 EP disclosed
US-20090286983-A1 Pyrazolopyridine Derivates PALAU PHARMA, S.A. (ES) 2009-11-19 US disclosed
US-20090005377-A1 Pyrazolopyridine Derivates PALAU PHARMA, S.A. (ES) 2009-01-01 US disclosed
US-7468376-B2 Pyrazolopyridine derivates PALAU PHARMA, S.A. (ES) 2008-12-23 US disclosed
US-20060167040-A1 Pyrazolopyridine derivates J. URIACH Y COMPANIA S.A. (ES) 2006-07-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060167040-A1 Pyrazolopyridine derivates MAPK1, MAP4K2, MAP4K3 ADORA1 4004/4885ADORA2A 3463/4885ADORA2B 4238/4885
US-20090286983-A1 Pyrazolopyridine Derivates MAPK1, MAPK4, MAP4K2 ADORA1 4368/4885ADORA2A 3970/4885ADORA2B 4436/4885
US-20090005377-A1 Pyrazolopyridine Derivates MAPK1, MAPK4, MAP4K2 ADORA1 4368/4885ADORA2A 3970/4885ADORA2B 4436/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.